General Information of Drug (ID: DMWPGLS)

Drug Name
ASN100 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hospital-acquired pneumonia CA40.Z Phase 2 [1]
Ventilator-associated pneumonia PK81.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMWPGLS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cyrtominetin DM0JA9N Phlegmy cough SA80-SA8Z Phase 3 [3]
AR-301 DM2YQK8 Ventilator-associated pneumonia PK81.0 Phase 3 [4]
MEDI4893 DMXB4NL Ventilator-associated pneumonia PK81.0 Phase 2b [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus Alpha-hemolysin (Stap-coc hly) TT5FLYB HLA_STAAU Modulator [2]
Staphylococcus Five leukocidin toxins (Stap-coc lukF) TTKE96O LUKF_STAAU Modulator [2]

References

1 ClinicalTrials.gov (NCT02940626) Prevention of S. Aureus Pneumonia Study in Heavily Colonized, Mechanically Ventilated Subjects
2 Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8.
3 Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8.
4 Clinical pipeline report, company report or official report of Aridis Pharmaceuticals.
5 Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.